[BioUSA] The Strength of Celltrion Embracing the Entire Ecosystem... "Meeting Requests Explode"

Celltrion achieved significantly increased results this year at the Bio International Convention (BIO USA) by leveraging a portfolio that encompasses the entire bio ecosystem.

A view of the Celltrion promotional booth set up at the San Diego Convention Center in California, USA, where the BIO International Convention (BIO USA) was held.
[Photo by Lee Chunhee]

원본보기 아이콘

According to Celltrion on the 10th, a total of 1,600 visitors came to the Celltrion booth at BIO USA held from the 3rd to the 6th (local time) in San Diego, California, USA. This figure is about double compared to last year's total of 800. In particular, on the first day alone, 500 people visited the booth, far exceeding last year's 180. The number of partnering meetings with companies also exceeded the target of 150.

The company cited its business structure covering the entire bioindustry framework?from development to clinical trials, approval, and sales?as the background for these achievements. A Celltrion representative met at BIO USA explained, "While other companies hold meetings only in specific business areas such as Contract Development and Manufacturing Organization (CDMO) or new drug candidate portfolios, Celltrion covers all business sectors. Because we can discuss everything from new drug development to technology cooperation, sales collaboration, and bio cluster-related partnerships, we are receiving more meeting requests."

For example, biopharmaceuticals require a cold chain system with strict temperature control through refrigeration or freezing equipment during transportation due to their characteristics. The company explained, "One of the companies that gave us a business card today is a cold chain company," adding, "They requested a meeting expressing interest in transporting Celltrion’s pharmaceuticals." Regarding Celltrion’s core product group, biosimilars, inquiries have also been received from companies wanting to sell biosimilars developed by themselves using Celltrion’s distribution network. Currently, Celltrion supplies various drugs directly to medical institutions and pharmacies through its U.S. sales subsidiary, CelltrionUSA.

Additionally, Celltrion’s global status has been further elevated following the approval by the U.S. Food and Drug Administration (FDA) and the launch in March of the new autoimmune disease treatment drug, Jimptetra. A company official stated, "Following the success of biosimilars and the launch of new drugs, Celltrion’s value in the U.S. has increased," emphasizing, "Unlike biotech companies, we are at a stage where we have successfully made sales and generated revenue."

Reflecting this popularity, despite setting up a large booth of 139m²?1.5 times larger than last year?with a total of eight meeting spaces, all these meeting areas were reportedly in constant use. Through this BIO USA, Celltrion held meetings with companies across various fields including its main business of biosimilars, follow-up pipelines, antibody-drug conjugates (ADC), antibody new drugs, distribution sales, bio clusters, and open innovation. The company aimed to establish potential partnerships that could create synergy within Celltrion’s business areas, which have built a one-stop system for the bioindustry since the merger.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.